Furthermore, accumulating findings have also outlined the promising use of EPO (Zhu et al., 2009; Mok et al., 2012; Boesch et al., 2014) in the treatment of retinal degenerative diseases, such as AMD (Wang et al., 2009), retinitis pigmentosa, and diabetic retinopathy (McVicar et al., 2011). This evidence concerns the gene EPO and retinitis pigmentosa.